Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS.

Limmroth V, Barkhof F, Desem N, Diamond MP, Tachas G; ATL1102 Study Group..

Neurology. 2014 Nov 11;83(20):1780-8. doi: 10.1212/WNL.0000000000000926. Erratum in: Neurology. 2015 Jan 6;84(1):105.

2.

A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-I production and body weight gain in normal mice.

Tachas G, Lofthouse S, Wraight CJ, Baker BF, Sioufi NB, Jarres RA, Berdeja A, Rao AM, Kerr LM, d'Aniello EM, Waters MJ.

J Endocrinol. 2006 Apr;189(1):147-54.

Supplemental Content

Loading ...
Support Center